This biotechnology startup develops peptides that modulate gene expression to normalize tumor microenvironments, enhancing the efficacy of immunotherapies and chemotherapies. By improving treatment responses, the company aims to enable patients to access earlier stages of cancer care, ultimately increasing survival rates and quality of life.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments like immunotherapies and chemotherapies often face challenges due to the tumor microenvironment, which can hinder drug delivery and reduce treatment effectiveness. This resistance limits the ability of these therapies to target and eliminate cancer cells effectively.
Solution
This biotechnology startup engineers peptides designed to modulate gene expression within the tumor microenvironment, effectively normalizing it to enhance the efficacy of existing cancer treatments. By modifying the tumor's surroundings, the peptides aim to improve drug penetration, reduce immune suppression, and increase the sensitivity of cancer cells to both immunotherapies and chemotherapies. This approach seeks to overcome resistance mechanisms, leading to more effective tumor control and improved patient outcomes. The modulation of gene expression allows for a more targeted and personalized approach to cancer treatment.
Target Audience
The primary target audience includes pharmaceutical companies developing cancer immunotherapies and chemotherapies, as well as oncology researchers seeking to improve treatment efficacy.
Features
- Proprietary peptide engineering platform for designing tumor microenvironment modulators
- Targeted gene expression modulation to normalize the tumor microenvironment
- Enhanced drug delivery and immune cell infiltration into tumors
- Increased sensitivity of cancer cells to immunotherapies and chemotherapies